Back to Search
Start Over
Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy
- Source :
- Expert review of anticancer therapy. 21(8)
- Publication Year :
- 2021
-
Abstract
- Introduction: Among the oncogene-addicted non-small cell lung cancer patients, those bearing ALK rearrangement can be currently treated with next-generation ALK inhibitors. Brigatinib was first use...
- Subjects :
- 0301 basic medicine
Lung Neoplasms
Brigatinib
medicine.drug_class
03 medical and health sciences
0302 clinical medicine
Organophosphorus Compounds
hemic and lymphatic diseases
Carcinoma, Non-Small-Cell Lung
Medicine
Humans
Pharmacology (medical)
Anaplastic Lymphoma Kinase
ALK Rearrangement
Protein Kinase Inhibitors
business.industry
food and beverages
First line treatment
ALK inhibitor
030104 developmental biology
Pyrimidines
Oncology
030220 oncology & carcinogenesis
Cancer research
Non small cell
business
Subjects
Details
- ISSN :
- 17448328
- Volume :
- 21
- Issue :
- 8
- Database :
- OpenAIRE
- Journal :
- Expert review of anticancer therapy
- Accession number :
- edsair.doi.dedup.....0c5cdb02179107aa5e2a1464db208b53